Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a portuguese consensus

Revista Portuguesa de Pneumologia (English Edition)

Volumn 23, Issue 2, 2017, Pages 90-99

  Araujo D ^a,b   Padrao E ^a,b   Morais Almeida, M ^c   Cardoso, J ^d,e   Pavao F ^a   Leite, R B ^a,f   Caldas, A C ^a   Marques, A ^b,g  

^a CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^b Universidade do Porto   (Portugal)

^c Coordinator of Allergy Center of CUF Hospitals ^*  (Portugal)

^d Universidade de Lisboa   (Portugal)

^e NOVA MEDICAL SCHOOL   (Portugal)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g University of Porto   (Portugal)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Overlap syndrome; Portuguese consensus

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 6; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PNEUMOCOCCUS VACCINE; TRANSCRIPTION FACTOR RUNX2;

ASTHMA; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; EOSINOPHILIA; HUMAN; INFLUENZA VACCINATION; MORTALITY RATE; QUESTIONNAIRE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SCORING SYSTEM; SIX MINUTE WALK TEST; COMPLICATION; CONSENSUS; PORTUGAL; PRACTICE GUIDELINE; SYNDROME;

ASTHMA; CONSENSUS; HUMANS; PORTUGAL; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

EID: 85014436819     PISSN: None     EISSN: 21735115     Source Type: Journal    
DOI: 10.1016/j.rppnen.2016.11.005     Document Type: Article

References (95)

1. Global Initiative for Asthma. Global strategy for asthmamanagement and prevention. Available at: http://www.ginasthma.org[accessed 2016].
2. Global Initiative for Chronic Obstructive Lung Disease. Globalstrategy for the diagnosis, management, and preventionof chronic obstructive pulmonary disease. Available at: http://www.goldcopd.org[accessed 2016].
3. Sa-Sousa A, Morais-Almeida M, Azevedo LF, Carvalho R, Jac-into T, Todo-Bom A, et al. Prevalence of asthma in Portugal-The Portuguese National Asthma Survey. Clin Transl Allergy.2012; 2: 15.
4. Cardoso J, Ferreira JR, Almeida J, Santos JM, Rodrigues F, Matos MJ, et al. Chronic obstructive pulmonary disease in Portugal: Pneumobil (1995) and 2002 prevalence studies revisited. RevPort Pneumol. 2013; 19: 88-95.
5. Bárbara C, Rodrigues F, Dias H, Cardoso J, Almeida J, Matos MJ, et al. Chronic obstructive pulmonary disease prevalence inLisbon, Portugal: the burden of obstructive lung disease study. Rev Port Pneumol. 2013; 19: 96-105.
6. Joint project of GOLD and GINA. Diagnosis of diseases ofchronic airflow limitation: asthma, COPD and asthma-COPDoverlap syndrome (ACOS). Global Initiative for Asthma, GlobalInitiative for Chronic Obstructive Lung Disease. Availableat: http://www.ginasthma.organd http://www.goldcopd.org[accessed 2015].
7. Gibson PG, Simpson JS. The overlap syndrome of asthma andCOPD: what are its features and how important is it? Thorax.2009; 64: 728-35.
8. van den Berge M, Aalbers R. The asthma-COPD overlap syn-drome: how is it defined and what are its clinical implications?J Asthma Allergy. 2016; 9: 27-35.
9. Pereira AM, Morais-Almeida M, Sá e Sousa A, Jacinto T, Azevedo LF, Robalo Cordeiro C, et al. Environmental tobacco smokeexposure at home and smoking prevalence in the general Por-tuguese population-the INAsma study. Rev Port Pneumol.2013; 19: 114-24.
10. Aanerud M, Carsin AE, Sunyer J, Dratva J, Gislason T, Jarvis D, et al. Interaction between asthma and smoking increases therisk of adult airway obstruction. Eur Respir J. 2015; 45: 635-43.
11. Jenkins HA, Cherniack R, Szefler SJ, Covar R, Gelfand EW, SpahnJD. A comparison of the clinical characteristics of children andadults with severe asthma. Chest. 2003; 124: 318-1324.
12. Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, et al. Acute bronchodilator responsiveness and healthoutcomes in COPD patients in the UPLIFT trial. Respir Res.2011; 12.
13. Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, et al. Bronchodilator responsiveness as a phenotypic charac-teristic of established chronic obstructive pulmonary disease. Thorax. 2012; 67: 701-8.
14. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-yearfollow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998; 339: 1194-200.
15. Watson L, Vestbo J, Postma DS, Decramer M, Rennard S, Kiri VA, et al. Gender differences in the management and expe-rience of chronic obstructive pulmonary disease. Respir Med.2004; 98: 1207-13.
16. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. Bronchodilator responsiveness in patients with COPD. EurRespir J. 2008; 31: 742-50.
17. van den Berge M, Vonk JM, Gosman M, Lapperre TS, Snoeck-Stroband JB, Sterk PJ, et al. Clinical and inflammatorydeterminants of bronchial hyperresponsiveness in COPD. EurRespir J. 2012; 40: 1098-105.
18. Menezes AM, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, et al. Increased risk ofexacerbation and hospitalization in subjects with an overlapphenotype: COPD-asthma. Chest. 2014; 145: 297-304.
19. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S, et al. The clinical and genetic features of COPD-asthma overlapsyndrome. Eur Respir J. 2014; 44: 341-50.
20. Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Man-nino DM, et al. Chronic obstructive pulmonary disease andasthma-patient characteristics and health impairment. COPD.2014; 11: 256-66.
21. Miravitlles M, Soriano JB, Ancochea J, Muñoz L, Duran-TauleriaE, Sánchez G, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status.Respir Med. 2013; 107: 1053-60.
22. de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstruc-tive pulmonary disease (COPD): prevalence and risk factors inyoung, middle-aged and elderly people from the general popu-lation. PLoS ONE. 2013; 8: e62985.
23. Fu JJ, Gibson PG, Simpson JL, McDonald VM. Longitudi-nal changes in clinical outcomes in older patients withasthma, COPD and asthma-COPD overlap syndrome. Respira-tion. 2014; 87: 63-74.
24. Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH. Charac-teristics and self-rated health of overlap syndrome. Int J ChronObstruct Pulmon Dis. 2014; 9: 795-804.
25. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpeläinen M, Kinnula VL, et al. Overlap syndrome of asthma and COPDpredicts low quality of life. J Asthma. 2011; 48: 279-85.
26. Kitaguchi Y, Yasuo M, Hanaoka M. Comparison of pulmonaryfunction in patients with COPD, asthma-COPD overlap syn-drome, and asthma with airflow limitation. Int J Chron ObstructPulmon Dis. 2016; 11: 991-7.
27. Gao Y, Zhai X, Li K, Zhang H, Wang Y, Lu Y, et al. Asthma COPDoverlap syndrome on CT densitometry: a distinct phenotypefrom COPD. COPD. 2016; 13: 471-6.
28. Brzostek D, Kokot M. Asthma-chronic obstructive pulmonary dis-ease overlap syndrome in Poland. Findings of an epidemiologicalstudy. Postepy Dermatol Alergol. 2014; 31: 372-9.
29. Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW, et al. Burden of concomitant asthma and COPD in a Medic-aid population. Chest. 2008; 134: 14-9.
30. Gerhardsson de Verdier M, Adersson M, Kern DM, Zhou S, TurnceliO. Asthma and chronic obstructive pulmonary disease overlapsyndrome: doubled costs compared with patients with asthmaalone. Value Health. 2015; 18: 759-66.
31. Sorino C, Pedone C, Scichilone. Fifteen-year mortality ofpatients with asthma-COPD overlap syndrome. N Eur J InternMed. 2016; June. pii: S0953-6205 (16) 30189-3.
32. Hardin M, Silverman EK, Barr RG, Hansel NH, Schroeder JD, Make BJ, et al. The clinical features of overlap between COPD andasthma. Respir Res. 2011; 12: 127.
33. Iwamoto H, Gao J, Koskela J, Kinnula V, Kobayashi H, Laitinen T, et al. Differences in plasma and sputum biomarkers betweenCOPD and COPD-asthma overlap. Eur Respir J. 2014; 43: 421-9.
34. Calverley PM, Albert P, Walker PP. Bronchodilator reversibilityin chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013; 1: 564-73.
35. Postma DS, Reddel HK, ten Hacken NHT, van den Berge M.Asthma and chronic obstructive pulmonary disease: similaritiesand differences. Clin Chest Med. 2014; 35: 143-56.
36. Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma-COPD overlap syndrome? Towards aconsensus definition from a round table discussion. Eur RespirJ. 2016; 48: 664-73.
37. Gibson PG, McDonald VM, Marks GB. Asthma in older adults.Lancet. 2010; 376: 803-13.
38. Mauad T, Dolhnikoff M. Pathologic similarities and differencesbetween asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008; 14: 31-8.
39. Ravensberg AJ, Slats AM, van Wetering S, Janssen K, van Wijn-gaarden S, de Jeu R, et al. CD8 (+) T cells characterize earlysmoking-related airway pathology in patients with asthma. Respir Med. 2013; 107: 959-66.
40. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence andclinical characteristics. Eur Respir J. 2014; 44: 1697-700.
41. George L, Brightling CE. Eosinophilic airway inflammation: rolein asthma and chronic obstructive pulmonary disease. Ther AdvChronic Dis. 2015; 1: 18.
42. Chou KT, Su KC, Huang SF, Hsiao YH, Tseng CM, Su VY, et al.Exhaled nitric oxide predicts eosinophilic airway inflammationin COPD. Lung. 2014; 192: 499-504.
43. Tsutomu T, Hisatoshi S, Tsuneyuki T, Kazuto M, Keiji K, Uichiro K, et al. Biomarker-based detection of asthma-COPD overlapsyndrome in COPD populations. Int J Chron Obstruct Pulm Dis.2015; 10: 2169-76.
44. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, et al. Partial reversibility of airflow limitation and increasedexhaled NO and sputum eosinophilia in chronic obstructive pul-monary disease. Am J Respir Crit Care Med. 2000; 162: 1773-7.
45. Konstantellou E, Papaioannou AI, Loukides S, Patentalakis G, Papaporfyriou A, Hillas G, et al. Persistent airflow obstructionin patients with asthma: characteristics of a distinct clinicalphenotype. Respir Med. 2015; 109: 1404-9.
46. Cosio BG, Soriano JB, López-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de-Torres JP, et al. Defining the asthma-COPDoverlap syndrome in a COPD cohort. Chest. 2016; 149: 45-52.
47. Barrecheguren M, Esquinas C, Miravitlles M. The Asthma-COPDoverlap syndrome: a new entity? COPD Res Pract. 2015; 1: 8.
48. Fu JJ, McDonald V, Gibson P, Simpson JL. Systemic inflammationin older adults with Asthma-COPD overlap syndrome. AllergyAsthma Immunol Res. 2014; 6: 316-24.
49. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015; 373: 1241-9.
50. James A, Palmer L, Kicic E, Maxwell P, Lagan S, Ryan G, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005; 171: 109-14.
51. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence ofirreversible airflow limitation and reduced transfer coefficientin patients with asthma after 26 years of follow up. Thorax.2003; 58: 322-7.
52. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society publicpolicy statement: novel risk factors and the global burden ofchronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182: 693-718.
53. Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, et al. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLDstudy. Thorax. 2015; 70: 822-9.
54. Sparrow D, O’Connor G, Weiss ST. The relation of airwaysresponsiveness and atopy to the development of chronicobstructive lung disease. Epidemiol Rev. 1988; 10: 29-47.
55. Fattahi F, ten Hacken NH, Löfdahl CG, Hylkema MN, Timens W, Postma D, et al. Atopy is a risk factor for respiratory symptomsin COPD patients: results from the EUROSCOP study. Respir Res.2013; 14: 10.
56. de Marco R, Marcon A, Rossi A, Antó JM, Cerveri I, Gislason T, et al. Asthma, COPD and overlap syndrome: a longitudinal studyin young European adults. Eur Respir J. 2015; 46: 671-9.
57. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung functionover time in smokers with early chronic obstructive pulmonarydisease: the Lung Health Study Research Group. Am J Respir Crit Care Med. 1996; 153: 1802-11.
58. Burney CGJ, Britton JR, Chinn S, Tattersfield A, Papacosta A, Kelsonet M, et al. Descriptive epidemiology of bronchial reac-tivity in an adult population: results from a community study. Thorax. 1987; 42: 38-44.
59. Tashkin DP, Altose MD, Bleecker ER, Connett J, Kanner R, Lee W, et al. The Lung Health Study: airway responsiveness to inhaledmethacholine in smokers with mild to moderate airflow limita-tion. Am Rev Respir Dis. 1992; 145: 301-10.
60. Alshabanat A, Zafari Z, Albanyan O, Dairi M, Fitz Gerald J.Asthma and COPD overlap syndrome (ACOS): a systematicreview and meta analysis. PLoS ONE. 2015; 10: e0136065.
61. Slats A, Taube C. Asthma and chronic obstructive pulmonarydisease overlap: asthmatic chronic obstructive pulmonary dis-ease or chronic obstructive asthma? Ther Adv Respir Dis.2016; 10: 57-71.
62. Soler-Cataluna JJ, Cosio B, Izquierdo JL, López-Campos JL, Marín J, Agüero R, et al. Consensus document on the over-lap phenotype COPD-asthma in COPD. Arch Bronconeumol.2012; 48: 331-7.
63. Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatroukal J, Zak J, et al. Chronic Obstructive Pulmonary Disease: officialdiagnosis and treatment guidelines of the Czech Pneumologicaland Physiological society: a novel phenotypic approach to COPDwith patient oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157: 189-201.
64. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, et al. The asthma-chronic obstructive pulmonary disease over-lap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013; 6: 197-219.
65. Izquierdo-Alonso JL, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P, Unzueta I, Ribera X, Antón E, et al. Prevalence andcharacteristics of three clinical phenotypes of chronic obstruc-tive pulmonary disease (COPD). Respir Med. 2013; 107: 724-31.
66. Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto J, Kata-jisto M, et al. Diagnosis and pharmacotherapy of stable chronicobstructive pulmonary disease: the finish guidelines. Basic Clin Pharmacol Toxicol. 2015; 116: 291-307.
67. Miravitlles M, Alcazar B, Alvarez FJ, Bazús T, Calle M, Casanova C, et al. What pulmonologists think about the asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis.2015; 10: 1321-30. http://dx.doi.org/10.2147/COPD.S88667.
68. Gibson PG, McDonald VD. Asthma-COPD overlap 2015: now weare six. Thorax. 2015; 70: 683-91.
69. Cazzola M, Rogliani P. Do we really need asthma-chronicobstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016; 138: 977-83.
70. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): a diagnostic challenge. Respirology. 2016; 21: 410-8.
71. Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Under-standing asthma chronic obstructive pulmonary disease overlapsyndrome. Respir Med. 2016; 110: 1-11.
72. Caillaud D, Chanez P, Escamilla R, Burgel PR, Court-Fortune I, Nesme-Meyer P, et al. Asthma-COPD overlap syndrome (ACOS) versus pure COPD: a distinct phenotype? Allergy. 2016.
73. Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteris-tics and prevalence of asthma/chronic obstructive pulmonarydisease overlap in the United States. Ann Am Thorac Soc.2016; 13: 803-10.
74. Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, et al. Gender and asthma-chronic obstructive pul-monary disease overlap syndrome. J Asthma. 2016; 53: 720-31.
75. Ding B, Di Bonaventura M, Karlsson N, Ling X. Asthma-chronicobstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and Wellness Sur-veys. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1139-50.
76. Kiljander T, Helin T, Venho K, Jaakkola A, Lehtimäki L. Preva-lence of asthma-COPD overlap syndrome among primary careasthmatics with a smoking history: a cross-sectional study. NPJPrim Care Respir Med. 2015; 25: 15047.
77. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnickaet E, et al. COPD in never smokers: results from the population-based burden of obstructive lungdisease study. Chest. 2011; 139: 752-63.
78. Milanese M, Di Marco F, Corsico AG, Rolla G, Sposato B, Chieco-Bianchi F, et al. Asthma control in elderly asthmatics. An Italianobservational study. Respir Med. 2014; 108: 1091-9.
79. Andersen H, Lampela P, Nevanlinna A, Säynäjäkangas O, Keisti-nen T. High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J. 2013; 7: 342-63.
80. Weatherall M, Shirtcliffe P, Travers J, Beasley R. Use ofcluster analysis to define COPD phenotypes. Eur Respir J.2010; 36: 472-4.
81. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am JRespir Crit Care Med. 2011; 184: 662-71.
82. Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, et al. Proportional classifications of COPD phen-otypes. Thorax. 2008; 63: 761-7.
83. Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronicobstructive pulmonary disease, and mortality in the U.S. popu-lation. COPD. 2011; 8: 400-7.
84. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concom-itant asthma. Respir Med. 2008; 102: 50-6.
85. Chanez P, Vignola A, O’Shaugnessy T, Enander I, Li D, Jeffery P, et al. Corticosteroid reversibility in COPD is related to featuresof asthma. Am J Respir Crit Care Med. 1997; 155.
86. Brightling C, Monteiro W, Ward R, Parker D, Morgan M, Ward-law A, et al. Sputum eosinophilia and short-term response toprednisolone in chronic obstructive pulmonary disease: a ran-domised controlled trial. The Lancet. 2000; 356: 1480-5.
87. Nagai A, Aizawa H, Aoshiba K, Asano K, Hirata K, Ichinose M, et al. Guidelines for the diagnosis and treatment of COPD. 3rd ed. Tokyo (Japan): The Japanese Respiratory Society. Medical Review Co. Ltd.; 2009.
88. Chowdhury BA, The Dal Pan G. FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med.2010; 362: 1169-71.
89. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputumeosinophilia can predict responsiveness to inhaled corticos-teroid treatment in patients with overlap syndrome of COPDand asthma. Int J COPD. 2012; 7: 283-9.
90. Ishiura Y, Fujimurab M, Shibaa Y, Ohkurac N, Harac J, Kasaharac K. A comparison of the efficacy of once-dailyfluticasone furoate/vilanterole with twice-daily fluticasonepropionate/salmeterol in asthma-COPD overlap syndrome. Pulm Pharmacol Ther. 2015; 35: 28-33.
91. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaledcorticosteroid in smokers versus non-smokers with mild asthma.Thorax. 2005; 60: 282-7.
92. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus sal-meterol/fluticasone combination in patients with COPD. Int JCOPD. 2015; 10: 1015-26.
93. Tat T, Cilli A. Omalizumab treatment in asthma-COPD overlapsyndrome. J Asthma. 2016; 4: 1-3.
94. Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy inthe asthma-COPD overlap syndrome (ACOS) and its effects oncirculating cytokine levels. Immunopharmacol Immunotoxicol.2016; 38: 253-6.
95. Barnes PJ. Therapeutic approaches to asthma-chronic obstruc-tive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015; 136: 531-45.